[Continuous subcutaneous infusion of beta 2-agonists in infantile asthma].
Five infants aged 7 to 17 months were treated for asthma with a continuous subcutaneous infusion of a beta 2-agonist for 6 to 11 days in a dosage of 0.1 microgram/kg/mn. The patients had a severe attack of asthma with problems with infusions and/or problems with nebulizations of beta 2-agonists and/or bronchial stasis. No local or systemic adverse effects were recorded. This mode of administration of beta 2-agonists proved extremely useful, either as single therapy or as part of a therapeutic protocol including antibiotics, steroids and theophylline. It avoids the problems met with administration of beta 2-agonists by the other routes and allows the child freedom of movement. The main indication is the severe attack of asthma that fails to respond to nebulizations. We suggest this new therapeutic method should be included in the therapeutic armamentarium for infantile asthma, although its exact place and indications need to be further defined by studies in a larger number of patients.
Bremont
F
F
Unité des Maladies Respiratoires et Allergiques de l'Enfant et de l'Adolescent, CHU Rangueil, Toulouse.
Pienkowski
C
C
Moisan
V
V
Dutau
G
G
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002985:Clinical Protocols; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral / Q000295:instrumentation / Q000379:methods*
D000318:Adrenergic beta-Agonists